Based on our Methicillin-resistant Staphylococcus aureus (MRSA) and Hospital-Acquired Infections Pharmacor advisory services, Decision Resources is offering an exclusive analyst call entitled The Rising Threat of Gram-Negative Infections and Multi-Drug Resistant Gram-Negative Strains - News from ICAAC. Because this presentation features major updates, it is ONLY available to purchasers of one or both of these Pharmacor advisory services.

Hospital-acquired gram-negative infections represent an area of high unmet need and untapped drug development opportunity in the antibacterial market. Consistent with the expansion of antibacterial drug development focus to include gram-negative infections in addition to MRSA, the predominant theme at this year’s 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) event was the heightened awareness and rising threat of gram-negative infections, especially the increase in multi-drug resistant (MDR) gram-negative strains. Data presented at the conference strongly echoed clinicians’ concern over the immediate need for novel agents against MDR gram-negative pathogens.

Recorded live on Thursday, October 7, 2010


This 15-minute analyst call, presented by Decision Resources Analyst Charu Vepari, Ph.D., answers the following questions:

• In the competitive antibiotic market, which market segments (treatment by intent, pathogen, indication) hold the greatest opportunity for drug development and new therapeutic options?
• What are the most promising new gram-negative agents presented at ICAAC and what are physicians’ opinions of these drugs?
• What promising MRSA agents emerged at ICAAC? Do current drug development activities address the unmet needs for the treatment of MRSA infections? 

Contact us to learn how you can purchase this service and attend this event.

Click here to view the invite.